TrialThe Lancet. Haematology2015

Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.

Rosangela Invernizzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.